Biobanking  Americas     The future for next generation drug discovery and personalised medicines                        7...
Conference Introduction                                                                                                   ...
Pre-Conference Interactive Workshop                                                                                       ...
Day 1                                                                                                                     ...
Day 2                                                                                                                     ...
Registration Form                                                                                                         ...
Upcoming SlideShare
Loading in …5
×

Biobanking americas (2011)

951 views
893 views

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
951
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Biobanking americas (2011)

  1. 1. Biobanking Americas The future for next generation drug discovery and personalised medicines 7th - 9th June 2011, Boston, USA BOOK NOW! Key Speakers Dr. Marc Allard, Research Microbiologist, Center for Food Safety and Applied Nutrition, FDA Dr. Adel Laoui, Director, Healthcare Technologies Aging Therapeutic Strategic Unit, Sanofi-aventis Brenda Yanak, West Point IT Site Head and Account Manager, Franchise Biology, siRNA, Imaging, and GeM, Merck Jeff Milton, Bioinformatics & Computational Biology, Genentech Dr. John G. Baust, UNESCO Chair & Professor, Director, Institute of Biomedical Technology, State University of New York Elaine W. Gunter, Founder and President, Specimen Solutions, LLC Dr. Hartmut Juhl, CEO, Indivumed James Eliason, Director, Stem Cell Commercialization Center Dr. Michael Hehenberger, Business Development Executive, Life Sciences, IBM Thomas J. Watson Research Center Kristen Rosati, Partner, Coppersmith Schermer & Brockelman Dr. Richard J. Maguire, Director of Business Development – LIMS, Ocimum Biosolutions Dr Nicolas Goffard, Bioinformatician - Functional Analysis, Almac Diagnostics Jim Chinitz, Chief Executive Officer, Population Diagnostics Pre-conference Workshop, 7th June 2011 The role of best and evidence based practice in promoting quality sample and data collection to support biomarker research and development Led By: Lisa B Miranda, Vice President, Strategic Alliances and International Biobank Relations, Trans-Hit BiomarkersAssociate Sponsor Driving the Industry Forward | www.futurepharmaus.com Organised ByMedia Partners To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/biobankingamericas
  2. 2. Conference Introduction Biobanking Americas 7th - 9th June 2011, Boston, USAAn estimated $1bn has been invested in the biobanking industry Associate Sponsor:within the last ten years. At least 179 biobanks with 345,000 Nexus Biosystems provides high-integrity solutions for donors exist in the US, most of which were established in the last demanding Life Science applications. From Sample 10 years. (Source: Business Insights, March 2009) Storage to Sample Analysis, Nexus provides high- performance products and services to high-value discovery Dear Colleague, laboratories. Nexus provides the Universal Store line of Automated Biological IME Magazine highlighted biobanking as one of “10 Ideas Changing the World Right T and Chemical Compound Sample Storage, for highly-modular and expandable Now.” Biobanking is rapidly growing and thriving to change approaches to target- systems from -80°C, -20°C and ambient environments. Nexus manufactures finding, drug development and patient treatment. It is being viewed as a key driver for and sells its’ XPeel Automated Seal-Removal Systems enabling highly- next generation biomarker and drug discovery. automated systems to run unattended. Nexus markets the Aurora Microplate he substantial advancement of research on the human genome has led to the creation T Products for sensitive fluorescence and cellular-imaging applications in the of biobanks, which has brought a paradigm shift in drug testing and development. world’s leading assay development and screening settings. Recognizing the potential benefits from biobanks, pharma and biotech across the world are investing in infrastructure and biobank development. For further information please email: www.nexusbio.com iobanking Americas reflects the broad spectrum of strategic approaches in biosample B Media Partners: management. Visiongain is proud to be hosting this important conference, which will PharmiWeb.com is the leading industry-sponsored portal bring together a panel of experts, comprising scientists, regulators, researchers who for the pharmaceutical sector. Supported by most of the will provide you with practical knowledge and strategic advice on new models and theoretical frameworks of biobanking. In addition to this, the conference will enable leading pharmaceutical corporations, PharmiWeb.com provides dynamic participants to identify and overcome the ethical, legal and social challenges. real-time news, features, events listings and international jobs to industry professionals across Europe and the US.Reasons to register today: For further information please email: corporate@pharmiweb.com • Learn how to develop the best practices to leverage biospecimen resources BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY • Analyse major challenges for biorepository management and implementation WORLD. It is based and located in Warsaw, Poland. • Get the latest updates on the applications on genome sequencing Biotechnology World was founded in 2007 to provide the world’s biotech and • nvestigate the future of biobanks, regulation, ethics, investment and the humanization I pharma information and market to make it universally accessible and useful of drug discovery in the Americas for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick • Determine how to implement virtual biorepository spread of information in different channels. BIOTECHNOLOGY EUROPE offers • Understand the importance of quality management in biobanking companies completed internet public relations, publication and marketing • ain an insight into the bioprospecting of tissues, DNA, protein or genetic G solutions. One of the mains goals of BIOTECHNOLOGY EUROPE is to information integrate the Biotech and Pharma Sector in Europe to global biotechnology, • nable confident decision making by benchmarking yourself against other leaders in E pharmaceutical and life science activities. the field For further information please visit www.biotechnology-europe.com I look forward to meeting you at the conference Future Pharmaceuticals has forged powerful relationships Driving the Industry Forward | www.futurepharmaus.com Best regards with key industry leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma Pranita Nangia companies as well as small, specialty, and biotech, Future Pharmaceuticals Head of Conferences magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries’ top issues and the solutions top-tier vendors can provide. For further information please visit: www.futurepharmaus.com Who should attend? InPharm is the online platform for exclusive pharmaceutical VPs, Directors, Heads, Managers of: news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. • Biobank • Tissue bank For further information please visit: www.In-Pharm.com • Biorepository/BioSample • Molecular Diagnostics • Clinical Genetics, Pathology • Genomics Sponsorship and exhibition opportunities: • Privacy/Protection/Security • Scientific and Quality This event offers a unique opportunity to meet and do business with some • Laboratory and Inventory • R&D of the key players in the pharmaceutical and biotech industries. If you have a • Quality Control • Strategic Outsourcing service or product to promote, you can do so at this event by: • Clinical Research • Hosting a networking drinks reception • Translational Medicine • Personalized Medicine • Taking an exhibition space at the conference • Bioanalytical Chemistry • Pharmacogenomics • Advertising in the delegate documentation pack • Proteomics • Business development • Providing branded bags, pens, gifts, etc. • Strategic alliances If you would like more information on the range of sponsorship or exhibition Others: possibilities for visiongains Biobanking Americas Conference, please contact us: Consultants& Academics Regulatory bodies Researchers Ronald Magali, +44 (0)20 7549 9934 Biorepository Vendors ronald.magali@visiongainglobal.com Government Officials
  3. 3. Pre-Conference Interactive Workshop Biobanking Americas Tuesday 7th June 2011 The role of best and evidence based practice in promoting quality sample and data collection to support biomarker research and development Led by: Lisa B Miranda Timings: 9:30 - 10:00 Coffee & Registration 0 Vice President, Strategic Alliances and 10:00 - 15:00 Workshop International Biobank Relations T iming includes lunch and refreshment breaks Trans-Hit BiomarkersAbout the workshop: About your workshop leader:Many consider biobanks to be the crucial cornerstone ofbiomedical research through their provision of expertise and Lisa B Mirandaprocurement of high quality samples and well annotateddata to foster research. One’s ability to develop high utility, With over 20 years of experience, Ms. Mirandaimpactful, yet quality biobanking collections lies in the has a vast range of expertise in all aspects ofbiospecimen resource’s success in implementing current best Biospecimen Resource Research Management andpractice as well as the foresight to incorporate evidence Development. After 14 years in research at the Universitybased practice into daily operations. The role of the of Pennsylvania, Ms. Miranda attained internationalbiobanker is now expanding to include proactive pipeline prominence as Technical Director of the Tumor Tissue andplanning which incorporates these considerations to ensure Biospecimen Bank (TTAB) Core Facility. She served as thesuccessful “proof of concept” in translational research prime architect of the centralized biospecimen resourceefforts such as biomarker research and development. and led TTAB’s collaborative efforts in development of the NCI’s CaTissue Suite inventory management system and aThis interactive workshop will include discussion of: National Mesothelioma Virtual Bank with the University of• An overview of related best and evidence based practice Pittsburgh and the CDC. In 2006, she was recognized for her issues development of a Sustainable Cost Recovery Model which• The role and current implications of best and evidence was acknowledged as the gold standard by the United based practice in the biobanking workspace that relate to States National Cancer Institute’s Office of Biorepositories pipeline planning and Biospecimen Research (NCI OBBR). Since then she has• Strategies for how to navigate the R&D pathway and continued to establish and develop best practices for the build a biomarker discovery pipeline for your biobank that biobanking community through her role as a NIH Contractor integrates evidence based practice and Consultant for NCI OBBR and the Biospecimen Research for Molecular Medicine Offices, as well as current work on cost recovery for the ISBER Best Practices (2010 version). In addition to collaborating on development of the Ca About Trans-Hit Biomarkers Inc: Hub, which is aimed at developing a common biorepository infrastructure that promotes resource sharing and team Trans-Hit Biomarkers is a privately held company whose science, in order to facilitate multi-institutional, high mission is to advance innovative biomarkers into more throughput genomic and proteomic studies, Ms. Miranda valuable and competitive products. Trans-Hit Biomarkers recently authored a new chapter for the NCI Best Practices is collaborative research organization forging strong focusing on Technical Considerations for Management and partnerships between human biobanks, preclinical CROs, Operations of Biospecimen Resources. In her role as member diagnostic companies and technology transfer offices. of the Ca Hub Acquisition of Normal Tissues Working For further information, please visit: http://www.trans-hit.com/ Group, she collaborated with her ANTWG colleagues on development of an additional best practice document focusing on procurement of post mortem tissues. In 2008, she expanded her consultancy with the incorporationAbout visiongain: of Biobusiness Consulting Inc., which serves the globalVisiongain is a specialist business information company focused on providing cutting biobanking research communities in government, academia,edge products and services across the Pharmaceutical/Biotech, Telecommunications, pharmaceuticals, biotech and related industry.Defence and Finance sectors, which include reports, conferences, online daily news andoffline news analysis and bespoke consultancy. With a commitment to innovation and Ms. Miranda is also active in numerous professionalexcellence, visiongain offers flexible solutions to meet our clients’ business intelligence societies and committees and has gained recognition asneeds, providing the right information at the right time to facilitate the commercial an international speaker and an expert in Biobanking.decision-making process. Our pharmaceutical products include Pharma Business Daily, Her current roles include: Councilor on the ISBER Board ofthe leading daily email newsletter for the pharmaceutical, biotech and healthcare Directors, membership in the global “think tank” knownindustries, and a range of independent, high-quality, in-depth reports covering focused as the “Marble Arch International Working Group onand topical areas of concern. Our pharmaceutical conferences address the hottestcommercial, regulatory and technical topics and provide an ideal forum for debate and Biobanking for Biomedical Research”, as well as P3G Societynetworking for pharmaceutical professionals from around the world. (Public Population Project in Genomics), LRIG and the NIH Biospecimens Special Interest Group.For further information, please visit: www.visiongain.com
  4. 4. Day 1 Biobanking Americas Wednesday 8th June 201109:00 Registration and refreshments 13:40 Science guided biobanking: A prerequisite for the development of individualized cancer therapies09:30 Opening address from the chair • issues are under tremendous biological stress when surgically separated T from the body and, subsequently, significantly change gene and protein expression profile and, possibly, also growth regulating factors that might 09:40 NCI’s Cancer Human Biobank (caHUB): Raising the serve as targets or stratification markers for new drugs. level of excellence for research biorepositories • everal factors have been identified that affect tissue research S • The vision for caHUB data, including: • Planning process for caHUB - rug treatment and anesthesia of patients before surgical tissue removal d - intrasurgical ischemia by ligation of main arteries (warm ischemia) • caHUB as a national reference repository - cold” ischemia, i.e. the time interval between surgical removal and “ • Challenges in bioethics and IP fixation of tissue • White papers available on caHUB operations - location of tumor biopsy within a given tumor Elaine W. Gunter - processing of tissue and fixation protocols Founder and President • onsequently, biobanks for target discovery and drug development have C Specimen Solutions, LLC to be based on fully controlled, well-documented processes that start already presurgery and include rapid and standardized tissue preparation in the surgery unit10:20 The institutional virtual biobank Dr. Hartmut Juhl • iscuss strategies, tools and techniques used for institutional federation D CEO, Indivumed and Inostics and curation of large volumes of disparate data, and present a case-study Adjunct Professor, Georgetown University for a workflow from repositories to data analysis Adjunct Professor, University of Hamburg • eveloping a cost-effective workflow to permit computational analysis will D become essential to scientific investigations 14:20 Recent Legal Developments in Biobanking • he HITECH Act, the HIPAA Privacy Rule amendments, and their impact T • igh-throughput experimental techniques threaten to dump mountains H on biobanking of new data onto bioinformatics teams already struggling with the • he affect of the Genetic Information Nondiscrimination Act on informed T diversity, complexity and enormity of existing resources consent for biobanking Jeff Milton • nd more! A Bioinformatics & Computational Biology Kristen Rosati Genentech Partner Coppersmith Schermer & Brockelman11:00 Morning refreshments 15:00 Afternoon Refreshments11:20 The importance of an Honest Broker function for clinical data associated with biospecimens 15:20 Sponsor Spotlight Session • hat is an Honest Broker in biobanking? W T ake this unique opportunity to be a part of our conference theme, network and provide an overview of your product/services to the audience. • hy is it needed for research? W F or more information please contact ronald.magali@visiongainglobal.com • hat types of research does it support? W • ow does it work? H 16:00 Biobanking: A key resource for deciphering the James Eliason molecular basis of cancer subtypes Director • hallenges for data mining and integration of clinical information with C Stem Cell Commercialisation Center functional genomics data • ecent developments of effective strategies R12:00 Biobanking in the Post-genomic Era: • pplication to prostate cancer subtypes A Methodological Challenges Dr Nicolas Goffard • Can current cryopreservation practices be defined as “best practices?” Bioinformatician - Functional Analysis Almac Diagnostics • an mitigation of cell stress molecular pathways improve biobanked C cellular products? 16.40 Cardiovascular Sample Repositories for the Human • ow does the end-user objective influence issues of “structural” H Cardiovascular Proteome versus “functional” cryopreservation? Dr. Mario Hugo Genero • Is biomarker integrity impacted by sub-optimal cryopreservation? Cardiovascular Initiative Human Proteome Organisation’s (HUPO) Dr. John G. Baust UNESCO Chair & Professor, Director 17.20 Closing remarks from the chair Institute of Biomedical Technology, State University of New York 17.30 Networking drinks12:40 Networking lunch Take your discussions further and build new relationships in a relaxed and informal setting Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011
  5. 5. Day 2 Biobanking Americas Thursday 9th June 201109:00 Registration and refreshments 14:20 The Gene Partnership: Implementing the ‘Informed Cohort’ model for the ethical recruitment and09:30 Opening address from the chair engagement of participant into genomic research • Description of the project at Children’s Hospital Boston09:40 Next Generation sequencing at the FDA Center for • Return of research results through a personally controlled health record Food Safety and Applied Nutrition. Trace back and • versight of return of research results: the “Informed Cohort O testing of foodborne pathogens Oversight Board (ICOB)” • he milestones for this project included: the ability to provide all of the T • Implications for personalized medicine data generated from analysis of Salmonella enterica genomes Dr. Ingrid A. Holm • eveloped software that will provide full contig assembly of 454 D CASE STUDY Director Phenotyping Core, Program in Genomics genomic data, annotation of those contigs and then generate lists of Divisions of Genetics and Endocrinology, genes present in each Salmonella genome based on annotation analysis. • ecent Next gen experience in building a comparative genomics lab R Children’sHospital Boston that is directly testing the applications of these methods for foodborne pathogen outbreak detection and analysis 15:00 Afternoon refreshments Dr. Marc Allard Research Microbiologist, Microbiology 15:20 Biobanking: The Lynchpin for Translational Research FDA-CFSAN-ORS • So, what’s an imperative for the Biobank? - he Quality of the specimens, diseased and normal, must be T10:20 Presentation to be announced absolutely maintained Brenda Yanak - he real value of a Biobank, in either context, is the Meta data (patient T West Point IT Site Head and Account Manager, Franchise Biology, demographics, diagnosis, cohorts, environmental exposure, behavior siRNA, Imaging, and GeM (smoker/non-smoker), etc. Merck - Whether de-identified or anonymized, or with PHI (Patient Health 11:00 Morning refreshments Information), the intrinsic value of biospecimens is in how well and how thoroughly the specimens are annotated11:20 Integrated Healthcare Technologies Solutions for - n the Pharma context, it is also an imperative to validate the biomarker I an Aging Society information via SNP Genotyping, Gene Expression, Flow Cytometry or • harmaceutical company moving towards global healthcare corporation P Mass Spectrometry. • ealthcare paradigm shift from traditional inpatient care towards H - n Medical Research, it essential to track the genealogy of child samples I home-based care downstream form the Biobank with a referential link to the parent • evelop solutions that span from Wellness to Illness care D specimen, as that is where the patient Meta data is stored. • ole of Informatics to enable a consumer healthcare business model R Dr. Richard J. Maguire • ision-Gain from a true integrated and diversified healthcare system V Director of Business Development – LIMS Adel Laoui Ocimum Biosolutions Director, Healthcare Technologies Aging Therapeutic Strategic Unit Sanofi-aventis 16:00 Biobanking : New Developments in Genomics That May Impact Biobanks12:00 Sponsor Spotlight Session • he extent of human genetic variation is much greater than anyone T imagined. How does this alter gene discovery approaches and the patient T ake this unique opportunity to be a part of our conference theme, network samples required? and provide an overview of your product/services to the audience. • he importance of normal human variation and the use of samples from T F or more information please contact ronald.magali@visiongainglobal.com apparently healthy people. • ther paradigm shifts around disease heterogeneity such as rare varants O12:40 Networking lunch vs common variants and the how the impact to discovery and validation design alters biobank requirements.13:40 IT Solutions to support Biobanking • WAS produced fodder mostly for the DTC market segment, but what’s the G • iobanks are essential for the transformation of Healthcare, as we move B next generation of approaches to translate medicine that doctors can use. towards “translational science”, preventive care and personalized medicine. Jim Chinitz • T Solutions supporting Biobanks must address privacy and security concerns I Chief Executive Officer and should accommodate new data types such as genomic and imaging data Population Diagnostics • o provide value to the medical research community, IT solutions must T be capable of query and analysis and enable the creation of disease 16:40 Chair’s closing remarks specific repositories • xamples to be discussed will include Oncology and Neuroscience E 16:50 End of Conference Dr. Michael Hehenberger Business Development Executive, Life Sciences IBM Thomas J. Watson Research Center
  6. 6. Registration Form Biobanking Americas 7th - 9th June 2011, Boston, USAFor multiple bookingsPhotocopy this form Conf. code VGStandard Prices Biobanking AmericasConference and workshop Fee: £1699 (USD* 2629)Conference only Fee: £1299 (USD* 2010) 7th - 9th June 2011Workshop only Fee: £599 (USD* 927) Boston, USA*USD price is estimate onlyPromotional Literature DistributionDistribution of your company’s promotional literature to all conference attendees Fee: £999 VAT: £199.80 Total: £1198.80Details How to book Email: conferences@visiongainglobal.com Forename: Surname: Web: http://www.visiongain.com/biobankingamericas UK Office:Job Title: Company: Tel: +44(0) 20 7336 6100 Fax: +44(0) 20 7549 9932 Main Switchboard Number: Visiongain Ltd BSG HouseAddress: 226-236 City Road London EC1V 2QY UKCountry: Postcode: General information Venue: TBA, Boston, USA Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Phone: Fax: Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may be requested if payment has not been received in full before the event. Visiongain Ltd reserves the Email: right to charge interest on unpaid invoices. Substitutions/name changes or cancellations: There is a 50% liability on all bookings once Signature: made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice I confirm that I have read and agree to the terms and conditions of booking must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and Methods of payment substitutions must be from the same company or organisation and are not transferable between Payment must be made in sterling countries. Please note that discounted delegates places at a visiongain event are non refundable. Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, By Mail: Complete and return your signed registration form together with your cheque payable excluding substitutions/name changes, requested by the customer. This will be charged to the to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK customer by credit card prior to the changes being made. Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive By Fax: Complete and fax your signed registration form with your credit card details briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled to +44 (0) 20 7549 9932 due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details expenses, which may be incurred by the customer as a consequence of the event being postponed or By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the cost of the registration, travel and expenses.By Bank Transfer: Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1988. Your personal information contained in this form may be used to update you on Visiongain Ltd A/C: visiongain Ltd visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We Barclays Bank Sort Code: 20-71-64 may also share your data with external companies offering complementary products or services. If you Piccadilly Branch Account No: 6038 7118 wish for your details to be amended, suppressed or not passed on to any external third party, please send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, 48 Regent Street Swift Code: BARC GB22 EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details. London, W1B 5RA IBAN: GB80 BARC 20716460387118 Please allow approximately 30 days for your removal or update request to be applied to our database. Following your removal or update request, you may receive additional pieces of communication from Please debit my credit card: visiongain Ltd during the transitional period, whilst the changes are coming into effect. Access MasterCard Visa American Express Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly recommend you obtain).Card number: VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com. Eurocash specialise in recovering cross-border VAT. How we will contact you: Visiongain Ltd’s preferred method of communication is by email and Expiry Date: phone. Please ensure that you complete the registration form in full so that we can contact you.Security number (last 3 digits on back of credit card): Unable to attend Obviously nothing compares to being there but you need not miss out. Simply tick the box and send Signature: with your payment. You will receive speaker talks in PDFs two weeks after the event. Yes, please send me speaker talks Price£550 VAT:£110 Total:£660Cardholder’s name: Office use onlyNews updatesPlease tick if you do not want to receive email news updates in the future www.visiongain.com/biobankingamericas

×